# 來源取得範圍與缺口 / Source scope and gaps

研究資料截至 / Research as of 2026-10-07。本索引列出本次來源補正涉及的 47 個來源；其餘來源的取得範圍保留於完整報告來源章。 / This index covers the 47 sources in the source supplement. Other source scopes remain in the complete report.

## R03

[原始來源 / Original source](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079096/)

- source_date: 2025-01-02
- data_date: 2020-09至2024-01檢測資料；卷期2025-05-15
- read_level: no_article_content_obtained
- access_result: reCAPTCHA; stopped
- precise_gap: The only reopened claim is the baseline low-level mutation detail. Table 1/case original text was not obtained; prior author summaries do not close this gap.
- current_disposition: Specified unavailable source-dependent example/detail removed; historical records retained; original evidence gap remains.

## R05

[原始來源 / Original source](https://pubmed.ncbi.nlm.nih.gov/26076429/)

- source_date: 2015-06-15
- data_date: 2015年臨床前研究
- read_level: 本輪未取得 PubMed 摘要；本地 foundations.json 的 claims 為作者摘要，未當原文
- access_result: 直接原 URL 回 Internal Error；原已用 turn40view0 讀回只有 HHS Vulnerability Disclosure 空殼，沒有摘要。停止，未用替代 route。
- precise_gap: 無本輪可核原摘要，不對 Lyon 原研究「降低高負載 ADC 疏水性影響清除及治療指數」作新驗證。原作者整理和研究題名不足以代替所需原文，亦不據讀取失敗判定原主張錯誤。
- current_disposition: Specified unavailable source-dependent example/detail removed; historical records retained; original evidence gap remains.

## R08

[原始來源 / Original source](https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-completes-equity-investment-in-summit-therapeutics.html)

- source_date: 2026-10-05
- data_date: 2026-10-05
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## R09

[原始來源 / Original source](https://heidelberg-pharma.com/images/managed/HDP-101-01_AACR2024_final.pdf)

- source_date: 2024
- data_date: 2024年AACR海報；本稿僅引用機制段落
- read_level: 原 URL 一頁 AACR 2024 海報 PDF 文字；僅 Introduction / Background 機制段
- access_result: 正常取得原 URL PDF 文字
- precise_gap: 支持 HDP-101 合成 amanitin / RNA polymerase II 機制；2024 海報較舊的臨床數據完全不作 2026 人體進展證據。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## C09

[原始來源 / Original source](https://pubmed.ncbi.nlm.nih.gov/40454632/)

- source_date: 2025-05-31
- data_date: 未明示 / Not specified
- read_level: 本輪未取得摘要或全文；既有 clinical_records 為作者整理，未作原文證據
- access_result: 原 URL 429 Too Many Requests；原已用 ref 仍回同一 429。停止，不改 URL、不加 headers。
- precise_gap: 缺可重新核對的原始摘要，不能本輪確認 Gastric04 的再活檢條件、OS 14.7/11.4 個月及 HR 0.70（95% CI 0.55–0.90）；未因此判定原數值錯誤。
- current_disposition: Specified unavailable source-dependent example/detail removed; historical records retained; original evidence gap remains.

## C10

[原始來源 / Original source](https://pubmed.ncbi.nlm.nih.gov/41125110/)

- source_date: 2025-10-19
- data_date: 未明示 / Not specified
- read_level: PubMed 原始論文公開摘要及書目；未讀期刊全文
- access_result: 正常取得原 URL 公開摘要
- precise_gap: 支持限摘要可見之 NPC 設計、ORR 及 TRAE；不以此來源核 TNBC、ESCC 或完整論文。摘要未明列確切 data cutoff，保持未知。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## C11

[原始來源 / Original source](https://news.bms.com/news/details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx)

- source_date: 2026-06-02
- data_date: 未明示 / Not specified
- read_level: BMS 原始公開公司公告；相關試驗設計、期中結果與合作段落，非期刊全文
- access_result: 正常取得原 URL 公開正文
- precise_gap: 中國三期期中資料及中國以外 BMS/SystImmune 共同開發有直接支持；公司地圖把合作不分地域概括為「全球合作」過寬，建議精確化。未把公司公告提升成期刊證據。
- current_disposition: Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.

## C12

[原始來源 / Original source](https://heidelberg-pharma.com/images/managed/HDP-101-01_IMS_poster.pdf)

- source_date: 2026-09-24
- data_date: 2026-09-03
- read_level: 原 URL 單頁 IMS 2026 海報的 web 工具 PDF 文字；僅必要研究設計、進展及安全性/PK-PD 段，未在本輪核圖像
- access_result: 直接 URL 首次工具報 not accessible；原已用 turn62view0 正常回讀同一 URL 單頁 PDF 文字（不是替代 URL）。
- precise_gap: 支持早期 RRMM 劑量/進展與給藥管理；未證明實體癌的 prior Topo-I ADC 療效，也未將模型或單臂資料作確認性治療窗比較。source_date 2026-09-24 按附件保留；本頁直接可核的是 2026-09-03 cutoff。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## C16

[原始來源 / Original source](https://www.astrazeneca.com/content/dam/az/PDF/2026/h1q2/H1-and-Q2-2026-results-clinical-trials-appendix.pdf)

- source_date: 2026-07-27
- data_date: 2026-07-27
- read_level: 154頁公司公開 PDF，只核 ADC 必要試驗列：印刷第15–16頁（PDF index14–15）及日期；未分析全份
- access_result: 正常取得原 URL PDF 文字；未保存或聲稱下載全 PDF
- precise_gap: 現版直接支持五項 anticipated data 時窗；不能單憑本版證明 Lung07 曾從舊 H2 2026 改期。未查其他年份原始版本，建議僅刪舊版比較子句。
- current_disposition: Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.

## C17

[原始來源 / Original source](https://clinicaltrials.gov/study/NCT06382142)

- source_date: 2024-04-24
- data_date: 2026-07-23
- read_level: 已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取
- access_result: 已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代
- precise_gap: 限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## C21

[原始來源 / Original source](https://clinicaltrials.gov/study/NCT04622319)

- source_date: 2020-11-09
- data_date: 2026-05-15
- read_level: 已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取
- access_result: 已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代
- precise_gap: 限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## C22

[原始來源 / Original source](https://clinicaltrials.gov/study/NCT04784715)

- source_date: 2021-03-05
- data_date: 2026-07-30
- read_level: 已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取
- access_result: 已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代
- precise_gap: 限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## C23

[原始來源 / Original source](https://clinicaltrials.gov/study/NCT06203210)

- source_date: 2024-01-12
- data_date: 2026-08-06
- read_level: 已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取
- access_result: 已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代
- precise_gap: 限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## C24

[原始來源 / Original source](https://clinicaltrials.gov/study/NCT05629585)

- source_date: 2022-11-29
- data_date: 2026-06-15
- read_level: 已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取
- access_result: 已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代
- precise_gap: 限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D04

[原始來源 / Original source](https://www.merck.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer/)

- source_date: 2024-06-26
- data_date: 2024-06-26
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D05

[原始來源 / Original source](https://www.merck.com/news/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn/)

- source_date: 2025-05-29
- data_date: 2025-05-29
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D07

[原始來源 / Original source](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen)

- source_date: 2023-12-14
- data_date: 2023-12-14
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- precise_gap: The phrase no longer independently listed is not stated as an exchange delisting fact in the retrieved release. Full ownership is directly supported; a narrower ownership statement is proposed.
- current_disposition: Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.

## D10

[原始來源 / Original source](https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen)

- source_date: 2024-02-12
- data_date: 2024-02-12
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D12

[原始來源 / Original source](https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html)

- source_date: 2023-04-03
- data_date: 2023-04-03
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D13

[原始來源 / Original source](https://en.dualitybiologics.com/news/615.html)

- source_date: 2026-08-28
- data_date: 2026-06-30
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D14

[原始來源 / Original source](https://investors.gilead.com/news/news-details/2024/Gilead-and-Tubulis-Enter-Into-Exclusive-Option-and-License-Agreement-to-Develop-ADC-Candidate-for-Select-Solid-Tumor-Target/default.aspx)

- source_date: 2024-12-03
- data_date: 2024-12-03
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- precise_gap: No evidence of later option exercise/payment is claimed. The computed 465 figure needs an explicit royalties-excluded scope if described as a maximum.
- current_disposition: Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.

## D15

[原始來源 / Original source](https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline)

- source_date: 2026-04-07
- data_date: 2026-04-07
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- precise_gap: The returned extraction did not expose a separate publication date header. Source/data date 2026-04-07 is retained verbatim from the supplied attachment, not relabeled as newly confirmed by a header. Completion and net acquired-cash amounts require the already-cited D16/D17 and are not supported by this pre-close announcement alone.
- current_disposition: Agreement terms retained. Original publication date retained with explicit unverified-header qualification; closing and accounting stay with D16/D17.

## D18

[原始來源 / Original source](https://en.dualitybiologics.com/news/614.html)

- source_date: 2026-08-28
- data_date: 2026-08-28
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D21

[原始來源 / Original source](https://www.lonza.com/news/2026-06-30-07-00)

- source_date: 2026-06-30
- data_date: 2026-06-30
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D22

[原始來源 / Original source](https://www.lonza.com/media-advisories/2026-02-19-09-00)

- source_date: 2026-02-19
- data_date: 2026-02-19
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D23

[原始來源 / Original source](https://wuxixdc.com/wuxi-xdc-celebrates-gmp-release-of-singapore-site-ushering-in-a-new-era-of-global-expansion/)

- source_date: 2026-09-22
- data_date: 2026-09-21
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D24

[原始來源 / Original source](https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html)

- source_date: 2024-11-07
- data_date: 2024-11-07
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D26

[原始來源 / Original source](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm)

- source_date: 2026-08-04
- data_date: 2026-06-30
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## D27

[原始來源 / Original source](https://newsroom.astellas.com/2026-09-18-padcev-in-combination-with-keytruda-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-resectable-mibc)

- source_date: 2026-09-18
- data_date: 2026-09-18
- read_level: web_extracted_relevant_primary_source_sections
- access_result: specified original public URL returned the necessary text; no access-control block encountered
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T01

[原始來源 / Original source](https://www.obipharma.com/what-we-do/pipeline-overview/)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 原頁未標發布或更新日；這是本輪公開頁讀取，不是具日期的歷史快照。公司工程優勢不當成人體優效。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T02

[原始來源 / Original source](https://clinicaltrials.gov/study/NCT06480240)

- source_date: 2024-06-28
- data_date: 2025-08-08
- read_level: targeted_official_registry_API_fields
- access_result: HTTP 200, official API JSON read
- precise_gap: 此登錄不支持偶聯技術比較或人體療效結論；它僅支持OBI-992的登錄狀態與条件監看。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T03

[原始來源 / Original source](https://clinicaltrials.gov/study/NCT07124117)

- source_date: 2025-08-15
- data_date: 2026-01-05
- read_level: targeted_official_registry_API_fields
- access_result: HTTP 200, official API JSON read
- precise_gap: 此登錄不單獨支持GlycOBI工程差異；T01支持技術設計。沒有把尚未公布的PK、劑量或活性寫成已證實。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T04

[原始來源 / Original source](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/obi-pharma-and-tegmine-therapeutics-sign-exclusive-global-license-agr-1126261)

- source_date: 2026-01-12
- data_date: 2026-01-12
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 這份ACCESS發稿沒有寫2025年12月初始公告或兩次公告屬同一交易；舊研究摘要的該說法沒有存下真原文。本輪依指示未探讀OBI受保護旧公告，故日期／同一交易對應尚未驗。
- current_disposition: Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.

## T05

[原始來源 / Original source](https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed)

- source_date: 2026-08-03
- data_date: 2026-08-03
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 本公告未提GNX102或其裸抗體身份，不能以這份來源直接證明該舊分子的種類；GNX1021一期節點與bLeB/Y標的不受此缺口影響。未另核監管或登錄。
- current_disposition: Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.

## T06

[原始來源 / Original source](https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/)

- source_date: 2026-08-28
- data_date: 2026-08-28
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 支持CTA遞交與公司描述的臨床前相似性，不支持CTA已獲准、已給藥或相似藥已核准。未以頁面市场數字扩充本次範圍。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T07

[原始來源 / Original source](https://www.formosapharma.com/formosa-pharmaceuticals-announces-presentation-of-tsy-310-at-the-2026-asco-annual-meeting/)

- source_date: 2026-05-22
- data_date: 2026-05-22
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 該舊公告支持已呈現資料屬臨床前，但未獨立證明截至2026-10-07仍未進入人體；建議把持續階段敘述限定為公告的資料層級。
- current_disposition: Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.

## T09

[原始來源 / Original source](https://www.eirgenix.com/antibody-drug-conjugate)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 頁面未標資料日；不能由服務頁推定特定ADC商業訂單、客戶批次已放行或收入。未採過時的ADC核准總數或其他槽體尺度。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T10

[原始來源 / Original source](https://www.formosalab.com/tw/bioconjugation-adc)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 未標資料日；能力／供藥經驗為公司說法。15件專案與50Kg願景未作當期訂單或產能採用，也不以本頁證實產品別放行。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T11

[原始來源 / Original source](https://www.formosalab.com/tw/adc)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 原頁未標更新日；容積不是每批合格ADC公斤數、年產量、稼動率、商業銷量或營收。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T12

[原始來源 / Original source](https://www.mycenax.com/news-detail.php?id=122&lang=en)

- source_date: 2025-10-31
- data_date: 2025-10-31
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 不是全部產品／全部用途的全球專屬權利；公告未提供具名ADC商業批次或訂單收入，抗體一期不移植為ADC一期。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T13

[原始來源 / Original source](https://www.mycenax.com/cdmo.php?id=56)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 未標資料日；50 L並非產品別放行量、年產量、訂單或營收；未宣稱anti-IF ADC已進入一期。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T15

[原始來源 / Original source](https://www.twse.com.tw/pdf/ch/4746_ch.pdf)

- source_date: 未明示 / Not specified
- data_date: 2026-10-06
- read_level: public_PDF_page_1_text_extraction
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 附件原data_date為2026-10-06，原PDF未保存；本輪同URLPDF明列產製日期2026-10-07。上市／代號可由新讀支持，不能宣稱10/06原快照已核。
- current_disposition: Reader date scope corrected to the observed 2026-10-07 PDF; original 2026-10-06 snapshot remains unavailable and is not treated as verified.

## T16

[原始來源 / Original source](https://www.twse.com.tw/pdf/ch/6589_ch.pdf)

- source_date: 未明示 / Not specified
- data_date: 2026-10-07
- read_level: public_PDF_page_1_text_extraction
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 本輪新讀PDF日期與原data_date一致，原PDF位元組未存，不能主張原件hash一致；本輪只讀所需第1頁文字。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T17

[原始來源 / Original source](https://www.twse.com.tw/pdf/ch/6838_ch.pdf)

- source_date: 未明示 / Not specified
- data_date: 2026-10-07
- read_level: public_PDF_page_1_text_extraction
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 本輪新讀PDF日期與原data_date一致，原PDF位元組未存，不能主張原件hash一致；本輪只讀所需第1頁文字。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T18

[原始來源 / Original source](https://www.obipharma.com/investor-overview/corporate-overview/)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 未標頁面更新日；這是公司官方上市櫃資訊，不延伸成ADC臨床或合作證據。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T19

[原始來源 / Original source](https://glyconex.com.tw/investors/)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 未標頁面更新日；本輪只核上市櫃身分，未採該頁其他財務數字。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.

## T20

[原始來源 / Original source](https://www.mycenax.com/shareholders-meeting.php?id=5&lang=tw)

- source_date: 未明示 / Not specified
- data_date: 未明示 / Not specified
- read_level: targeted_public_HTML_passages
- access_result: specified public URL returned readable content; no access barrier encountered
- precise_gap: 未標頁面更新日；本輪只核上市櫃身分，不用此頁證實ADC能力。
- current_disposition: Original assigned contribution retained within the stated read level and boundary.